ULB and European Center for prevention and Control of Diseases fellow - FNRS
" In support of clinical biology laboratories, the ULB has set up a diagnostic plateform in both Erasmus and Gosselies campus to face the epidemic of SARS-CoV2. The diagnosis relies on the detection of viral RNA in nasal swab. The COVID plateform has the capacity to analyse 500 samples per day, 7 days a week and relies on the expertise and skill of more than 200 volunteers. "
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.
Comment: List of all the volunteers who are working in the COVID plateform

ULB, CHU Saint-Pierre, Hôpital Erasme, ULiège - FNRS

" The project investigates the immune responses to SARS-CoV-2 infection in humans. Cohorts of patients and contacts are recruited and followed-up during several months following infection. Using systems serology and systems biology approaches, the quality and dynamics of antibody and cellular responses are analysed to identify correlates of protection against severe disease and to determine the duration of natural immunity to the virus. The project should provide insight in the host response to SARS-CoV-2 and should help define deconfinement strategies and develop prophylactic and therapeutic interventions against COVID-19. "
Funding: COVID 19 - ULB
Contact: Arnaud Marchant: This email address is being protected from spambots. You need JavaScript enabled to view it. Stanislas Goriely: This email address is being protected from spambots. You need JavaScript enabled to view it.

ULB, Bordet Institute and CHU Saint-Pierre
" The limited capacity of intensive care unit (ICU) beds and the high mortality of patients requiring ICU care after COVID-19 infection are major problems that urgently require solutions. Early evidence suggests that an individual patient's immune responses to this virus are a key factor in their disease pathogenesis. This response can be further compounded by underlying factors, which for patients at Bordet can be exacerbated by their cancer status. A recent study shows that some cancer patients (particularly lung, blood or metastatic cancer patients) are three times more likely to die from COVID-19 infection. Thus, there is an important need to understand and identify immune biomarker(s) that measure functionality of innate and/or adaptive immunity in the blood with rapid turnaround to provide much needed information for clinical decision making. The anticipated results of this collaborative research project include the identification of...

Read more: Ahmad Awada, Chef de Service, Medical Oncology - Karen Willard-Gallo, Laboratory Head, Molecular...

UMONS/ Haute école Condorcet/ UCLouvain/ Epicura/ Machine sight
" In view of the risk of a respirator shortage in intensive care units throughout the world following the COVID 19 epidemic, a simple solution based on existing means or means that are easy to implement is being sought by a consortium of respiratory physiotherapists, researchers of UMONS, physicians of the the intensive care unit of the Epicura hospital and a mechatronics engineering company. In view of the risk of a respirator shortage in intensive care units throughout the world following the COVID 19 epidemic, a simple solution based on existing means or means that are easy to implement is being sought by a consortium of respiratory physiotherapists, researchers of UMONS, physicians of the the intensive care unit of the Epicura hospital and a mechatronics engineering company. "
Funding: internal funding
Contact: Pr. Alexandre Legrand, head of the laboratory of Physiology and Respiratory Rehabilitation...

Read more: Alexandre Legrand, Professor

Institut Jules Bordet
" Contribution to the application and implementation of a novel Covid-19 diagnostic testing method developed at the GIGA/FARAH academic research institutes. Starting with a handful academic scientists from different disciplines, we established a Covid diagnostic lab with the goal of increasing the testing capacity in Belgium during the heaviest period of the crisis. The lab was entirely and exclusively build by training academic volunteers dedicating their time and energy to a joint effort to "beat the virus". Today the lab has a testing capacity of > 3000 samples/day, 7days/7. The diagnostic lab contributed - and still contributes - to the federal Testing Task Force as one of the five partners involved in screening nursing homes and more recently "centres de triage". We believe extensive testing may be critical to assist and better understand the nascent "deconfinement". Making available our expertise in virus-associated diseases accumulated over years of...

Read more: Anne Van den Broeke, Doctor

UCLouvain, St-Luc
" We aim to characterize the reprogramming of structural cells of the lungs that are direct targets of the SARS-CoV-2, namely type 2 alveolar epithelial cells and endothelial cells, as well as their potential role in the induction of the (hyper)inflammatory phase of the disease leading to acute lung injury. The skills of our laboratory in lung and mucosal immunology research that are relevant to this field are (1) access to precious human lung tissue (e.g. from SARS-CoV-2 patients), (2) multiplex immunofluorescence staining and isolation of structural cells (e.g. alveolar epithelial cells, endothelial cells) from the human lung, as well as (3) their characterization using cell culture-based readouts and (in collab. with the UCL-CTMA) genetic sequencing. "
Funding: FNRS CUR, application submitted on 01-05-20.
Publication References: 1. Gohy ST, Hupin C, Fregimilicka C, Detry BR, Bouzin C, Gaide Chevronay H, Lecocq M, Weynand B, Ladjemi MZ, Pierreux CE, Birembaut P...

Read more: Charles Pilette, Professor

Institut Jules Bordet, ULB - FNRS
" Cancer patients under active treatment are thought to be highly vulnerable with regards to the current pandemic of COVID-19 disease. Their management has drastically changed over the past weeks, as clinics have been forced to adapt their care strategies according to national guidelines, postponing all non-essential consultations and having patients avoid the clinic altogether as much as possible. However, it is currently unclear if cancer patients are indeed at a higher risk of developing COVID-19 disease, and if systemic oncological treatment contributes to more severe disease because of suppression of the immune system, or rather protects against fatal cytokine release storms and acute respiratory distress syndromes. This information is absolutely crucial for the safety assessment of using cancer treatments during the COVID-19 pandemic, and for the monitoring of cancer patients during this period. Therefore, this project is a non-interventional...

Read more: Christos Sotiriou, FNRS Research Director

Erasme Hospital
" Objectifs : L'épidémie du coronavirus a eu des conséquences délétères sur la santé mentale de la population générale1,2. Aucune étude ne s'est encore penchée sur l'impact psychologique du coronavirus sur les proches des patients ayant été infectés par le covid-19. Cette étude permet de comparer les proches de patients survivants ayant séjourné ou n'ayant pas séjourné en soins intensifs, des proches de patients décédés. Méthodologie : Les familles (N=200) dont le proche a séjourné en soins intensifs ou en unité COVID à l'hôpital Erasme seront contactées par téléphone et invitées à compléter des questionnaires en ligne au minimum 1 mois après la sortie d'hospitalisation de leur proche, ou après son décès, et ensuite 6 mois après la première évaluation. Les variables psychologiques qui seront évaluées sont : (1) la qualité de vie (The Mc Gill Quality of Life Questionnaire), les symptômes anxieux et dépressifs (Hospital Anxiety and Depression Scale, HADS), les...

Read more: Delphine Canivet, PhD

ULiège, CHU de Liège, CIRM
" This study aims at measuring the activity of the Angiotensin-2 enzyme (AT2) by LCMS./MS in COVID patients. This enzyme plays a key-role in the mechanisms of the infection by the SARS-COV2 "
Funding: Fondation Leon Fredericq
Contact: Professor Etienne Cavalier Department of Clinical Chemsitry University of Liège, CHU de Liège This email address is being protected from spambots. You need JavaScript enabled to view it.

ULiege, CHU, GIGA I3
" Are obstructive diseases risk factors for developing pulmonary complications due to COVID19? We will include all patients followed up at CHU of Liege for COVID19 infection and classify them according to their underlying bronchopulmonary disease. The aim is to evaluate if asthma, severe asthma or chronic obstructive pulmonary diseases represent risk factors for developing pulmonary complications during COVID 19 infection. We want to find out biological or clinical predictors of complications. We also want to evaluate efficacy and safety of inhaled corticosteroids in asthma in case of COVID infection. Biomarkers will be measured at baseline and during follow-up. "
Funding: Fonds Leon Frederic
Contact: Schleich Florence, MD, PhD This email address is being protected from spambots. You need JavaScript enabled to view it. This email address is being protected from spambots. You need JavaScript enabled to view it.

UCLouvain, CHU UCLouvain/UNamur
" Evaluation of the thrombotic risk associated with SARS-CoV-2 infection and its management in the intensive care unit: a clinical and biological longitudinal study. Background Since the beginning of SARS-CoV-2 outbreak in December 2019, data accumulate regarding the high thrombotic risk associated with this infection, which could explain substantial part of the observed morbidity and mortality (1). Accordingly, a retrospective study suggested that prophylactic anticoagulation could reduce mortality in severe COVID-19 patients with sepsis-induced coagulopathy (2). Furthermore, a European cohort reported a 27% incidence of venous thrombo-embolisms (VTEs) despite systematic prophylactic anticoagulation, raising the question whether deeper anticoagulant regimen would be beneficial in severe COVID-19 (3). Some authors also suggested that fibrinolysis alterations could be a significant determinant of SARS-CoV-2 infection's prognosis, as it is in...

Read more: Francois Mullier, Prof - Alain Dive, Prof - Michael Hardy, Dr - Sarah Lessire, Prof - Isabelle...

ULiège, CHU - FNRS
" We aim to compare various diagnostic tools (swabs, saliva, serology, antigen detection) in order to define the best one depending on the clinical presentation and the duration of the disease. "
Funding: Fonds Léon Fredericq FNRS
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

ULiège, CHU - FNRS
" We aim to define the clinical characteristics associated with the production and the level of neutralizing antibodies (NAbs) in COVID19 recovered patients. In particular, we will investigate whether the development of a strong and persistent humoral immune response takes place in severely affected, individuals with mild symptoms or asymptomatic individuals. We will also study the study the persistence of NAbs overtime. "
Funding: Fonds Léon Frédéricq FNRS
Contact: This email address is being protected from spambots. You need JavaScript enabled to view it.

ULiège, CHU
" La recherche de biomarqueurs fiables, sensibles et peu invasifs est un enjeu de premier ordre pour la médecine moderne. En effet, ces biomarqueurs ont le potentiel de transformer la prise en charge médicale en améliorant le dépistage et le diagnostic, mais aussi en permettant de mieux appréhender la physiopathologie d'une pathologie ou sa réponse à un traitement donné. Fort de nos travaux précédents, nous proposons de réaliser une étude prospective sur une population adulte souffrant d'un SDRA modéré à sévère post SARS-COV2 afin de caractériser une signature exosomique plasmatique propre à cette population. "
Funding: FLF FIRS CHU de Liège
Publication References: hankar-Hari, M., Fan, E. & Ferguson, N. D. Acute respiratory distress syndrome (ARDS) phenotyping. Intensive Care Med. (2018). 45;(4): 516-519. Thompson BT, Chambers RC, Liu KD. Acute Respiratory Distress Syndrome. N Engl J Med. 2017;377(6):562–72. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C. Vesicle...

Read more: Gilles Parzibut, Doctor

ULB - FNRS
" - I use my expertise in clinical research to set up and coordinate the reception/labeling and encoding station at the COVID diagnostic platform at ULB - As new president of the BSRM, I coordinate the writing and diffusion o recommendations for the reproductive centers in Belgium regarding COVID-19 pandemic "
Contact: https://actus.ulb.be/fr/actus/recherche/tests-de-diagnostic-covid-19-plus-de-250-chercheurs-mobilises BSRM website (https://bsrm.be)
Comment: My role as president of the BSRM to manage the COVID-19 crisis and my participation as coordinator at the COVID diagnostic platform (ULB) are completely independent.